Suppr超能文献

慢性阻塞性肺疾病患者乳酸脱氢酶与白蛋白比值和短期死亡率的关系

Association Between Lactic Dehydrogenase-to-Albumin Ratio and Short-Time Mortality in Patients with Chronic Obstructive Pulmonary Disease.

作者信息

Yao Xiqing, Xue Haoyue, Luo Jiye

机构信息

Emergency Department, The First People's Hospital of Lianyungang, Lianyungang City, 222006, People's Republic of China.

出版信息

Int J Chron Obstruct Pulmon Dis. 2025 Jul 15;20:2435-2444. doi: 10.2147/COPD.S521192. eCollection 2025.

Abstract

PURPOSE

The lactate dehydrogenase-to-albumin ratio (LAR) has emerged as a prognostic marker for critically ill patients, yet its relationship with mortality in chronic obstructive pulmonary disease (COPD) remains poorly understood. Our purpose is to assess the predictive value of LAR in COPD patients.

PATIENTS AND METHODS

In this retrospective cohort study, data were extracted from the MIMIC IV database. COPD patients were divided into two groups based on 28-day all-cause mortality. To investigate the relationship between LAR and short-term mortality, multivariate Cox regression, receiver operating characteristic (ROC) analysis, and Kaplan-Meier survival analysis were performed.

RESULTS

The study included 1048 COPD patients, with 37% experiencing 28-day mortality. LAR was identified as an independent predictor of 28-day mortality (hazard ratio [HR] 1.01, 95% confidence interval [CI]: 1.01-1.01, P < 0.001). ROC analysis showed that LAR had an area under the curve (AUC) of 69.48% (95% CI: 65.67-73.29%), demonstrating superior discriminatory power compared to lactate dehydrogenase (AUC = 66.69%) or albumin (AUC = 36.88%) alone. Additionally, LAR's predictive performance was comparable to that of the Simplified Acute Physiology Score II (SAPSII), which yielded an AUC of 76.8% (95% CI: 73.54-80.06%). COPD patients with high LAR values (>120) had significantly higher 28-day mortality rates (P < 0.001).

CONCLUSION

Elevated LAR is an independent predictor of 28-day mortality in ICU patients with COPD. LAR proves to be a valuable prognostic tool that may assist in the early identification of high-risk patients with CPPD.

摘要

目的

乳酸脱氢酶与白蛋白比值(LAR)已成为危重症患者的预后标志物,但其与慢性阻塞性肺疾病(COPD)死亡率的关系仍知之甚少。我们的目的是评估LAR在COPD患者中的预测价值。

患者与方法

在这项回顾性队列研究中,数据取自MIMIC IV数据库。根据28天全因死亡率将COPD患者分为两组。为了研究LAR与短期死亡率之间的关系,进行了多变量Cox回归、受试者工作特征(ROC)分析和Kaplan-Meier生存分析。

结果

该研究纳入了1048例COPD患者,其中37%经历了28天死亡率。LAR被确定为28天死亡率的独立预测因子(风险比[HR]1.01,95%置信区间[CI]:1.01 - 1.01,P < 0.001)。ROC分析显示,LAR的曲线下面积(AUC)为69.48%(95%CI:65.67 - 73.29%),与单独的乳酸脱氢酶(AUC = 66.69%)或白蛋白(AUC = 36.88%)相比,具有更好的区分能力。此外,LAR的预测性能与简化急性生理学评分II(SAPSII)相当,SAPSII的AUC为76.8%(95%CI:73.54 - 80.06%)。LAR值高(>120)的COPD患者28天死亡率显著更高(P < 0.001)。

结论

LAR升高是COPD重症监护病房患者28天死亡率的独立预测因子。LAR被证明是一种有价值的预后工具,可有助于早期识别COPD高危患者。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/44af/12275921/69d1ca92271d/COPD-20-2435-g0001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验